CVS Health study finds GLP-1 medical savings fall short of drug costs

By Public Technologies
  • CVS Health today released research linking GLP-1 use to better clinical outcomes, fewer hospitalizations and lower medical spending.
  • Medical savings did not fully offset higher pharmacy spending at current drug prices.
  • Modeling suggested a net price of approximately $350 per month over three years would balance pharmacy spending with observed medical savings.
  • The analysis compared commercially insured Aetna GLP-1 users with matched non-users, covering treatment starts from 2023 through 2025.
  • Dr. Amy Compton-Phillips will discuss the findings later today at the HLTH industry conference in Las Vegas.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CVS Health Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611151000PR_NEWS_USPR_____NE97989) on November 15, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.